CAJ | 학술논문

目的：观察XELOX(卡培他滨+奥沙利铂)方案和mFOIFOX6(奥沙利铂+5-Fu+亚叶酸钙)方案治疗转移性结直肠癌的近期疗效及毒副反应。方法64例转移性结直肠癌患者随机分为XELOX组30例和mFOLFOX6组34例。 XELOX组给予奥沙利铂130 mg/m2,静脉滴注2 h,第1天；卡培他滨1000 mg/m2,分早晚2次口服,连用14 d；3周为1周期。 mFOLFOX6组给予奥沙利铂85 mg/m2,静脉滴注2 h,第1天；亚叶酸钙400 mg/m2,静脉滴注2 h后予5-氟尿嘧啶400 mg/m2,静脉推注,后续2400 mg/m2,持续静滴46 h,每2周重复,4周为l周期。患者均接受至少2周期的化疗。依据RESIST评价近期疗效,依据WHO标准评价毒副反应。结果XELOX组与mFOLFOX 6组有效率分别为43.3%和41.2%,两组中位疾病进展时间分别为5.5个月与6.0个月,差异无统计学意义(P>0.05)；XELOX组恶心呕吐发生率显著低于mFOIFOX6组(P<0.05)；XELOX组手足综合征发生率明显高于mFOLFOX 6组(P<0.05),但程度较轻,主要为Ⅰ~Ⅱ度。其他的毒副反应两组无明显差异(P>0.05)。结论XELOX方案与mFOLFOX6方案治疗转移性结直肠癌疗效确切且相似,毒副反应可耐受,XELOX方案更安全。
목적：관찰XELOX(잡배타빈+오사리박)방안화mFOIFOX6(오사리박+5-Fu+아협산개)방안치료전이성결직장암적근기료효급독부반응。방법64례전이성결직장암환자수궤분위XELOX조30례화mFOLFOX6조34례。 XELOX조급여오사리박130 mg/m2,정맥적주2 h,제1천；잡배타빈1000 mg/m2,분조만2차구복,련용14 d；3주위1주기。 mFOLFOX6조급여오사리박85 mg/m2,정맥적주2 h,제1천；아협산개400 mg/m2,정맥적주2 h후여5-불뇨밀정400 mg/m2,정맥추주,후속2400 mg/m2,지속정적46 h,매2주중복,4주위l주기。환자균접수지소2주기적화료。의거RESIST평개근기료효,의거WHO표준평개독부반응。결과XELOX조여mFOLFOX 6조유효솔분별위43.3%화41.2%,량조중위질병진전시간분별위5.5개월여6.0개월,차이무통계학의의(P>0.05)；XELOX조악심구토발생솔현저저우mFOIFOX6조(P<0.05)；XELOX조수족종합정발생솔명현고우mFOLFOX 6조(P<0.05),단정도교경,주요위Ⅰ~Ⅱ도。기타적독부반응량조무명현차이(P>0.05)。결론XELOX방안여mFOLFOX6방안치료전이성결직장암료효학절차상사,독부반응가내수,XELOX방안경안전。
Objective To compare the curative effect and adverse reaction of capecitabine, oxaliplatin (XELOX) and 5-fluorouracil(5-FU), leucovorin(LV), oxaliplatin (mFOLFOX6) in treatment of meta-static colorectal cancer. Methods 64 patients with metastatic colorectal cancer were enrolled into this study, 30 patients and 34 patients were randomly divided into XELOX group and mFOLFOX6 group respectively. XELOX group received oxaliplatin at the dose of 130mg/m2 by dropping on day 1 and oral administration of capecitabine at 1 000mg/m2 twice a day on day 1-14. mFOLFOX6 group was treated with oxaliplatin 85mg/m2 by dropping in 2-hour on day 1;LV 400 mg/m2 by dropping in 2-hour followed by 5-Fu 400 mg/m2 by inject and 5-Fu 2 400 mg/m2 by continue dropping for 46-hour. XELOX regimen was repeated every three weeks for one cycle;mFOLFOX6 regimen was repeated every two weeks and four weeks for one cycle. All patients received two cycles of chemotherapy at least. The curative effect was evaluated according to RESIST standards. The adverse reaction was evaluated according to WHO standards. Results The overall response rates of XELOX group and mFOLFOX6 group were 43. 3% and 41. 2% individually. The median time to progression (mTTP) were 5. 5 months in XELOX group and 6. 0 months in mFOLFOX6 group respectively. There was no statistical significance between the two groups (P>0. 05). In terms of adverse reactions,the incidence of grade Ⅰ to II side effect of digestive tract ( nausea and vomiting ) was significantly lower in XELOX group than that in mFOLFOX6 group (P<0. 05) ,but the incidence of hand and foot syndrome in XELOX group was more significantly than that in mFOLFOX6 group ( P<0 . 05 ) , but kept at light extent which mainly be gradedⅠtoII. The incidence of other adverse reactions has no statistical significance be-tween the two groups (P>0. 05). Conclusion XELOX regimen and mFOLFOX6 regimen are effective, two regimens have very similar curative effect with tolerable adverse reaction in treatment for metastatic colorectal cancer, but XELOX regimen may be safer than mFOLFOX6 regimen.